M&A Deal Summary |
|
|---|---|
| Date | 2022-04-27 |
| Target | Cend Therapeutics |
| Sector | Life Science |
| Buyer(s) | Lisata Therapeutics |
| Deal Type | Merger |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1980 |
| Sector | Life Science |
| Employees | 26 |
| Revenue | 1M USD (2024) |
Lisata Therapeutics is a late-stage therapeutics development biopharmaceutical company pioneering advancements in cell therapies in select cardiovascular and autoimmune diseases. Lisata Therapeutics was founded in 1980 and is based in Basking Ridge, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-04-14 |
California Stem Cell
Irvine, California, United States California Stem Cell, Inc. is a stem cell biotechnology company. CSC has developed proprietary methods for the scalable production of high-purity human stem cells and their derivatives. CSC has been focused on the application of these cells in developing life changing therapies, including Melapuldencel–T, which has been the subject of compelling trial results for the treatment of metastatic melanoma. |
Buy | - |
